Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Investigation of the Effectiveness of Spinal Stabilization Exercises Added to Aerobic Exercise in Women With Polycystic Ovary Syndrome

6 novembre 2026 aggiornato da: Emine Nacar, Inonu University

Polycystic ovary syndrome (PCOS) is a multisystemic disorder with metabolic and endocrine implications, commonly observed in women of reproductive age and characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Insulin resistance, chronic low-grade inflammation, hormonal imbalances, and obesity can contribute to reduced cardiorespiratory fitness and muscular endurance, in addition to the metabolic complications associated with PCOS. Furthermore, psychosocial effects such as depression, anxiety, and impaired quality of life may also occur. Lifestyle modifications and exercise are among the first-line approaches in the management of PCOS. Aerobic and resistance exercises have been reported to have positive effects on insulin resistance, cardiometabolic risk factors, hormonal profiles, inflammation, body composition, and reproductive functions. However, evidence regarding the specific effects of different exercise modalities on physical fitness components-such as cardiovascular and muscular endurance, which are adversely affected in PCOS-remains limited. Spinal stabilization exercises constitute an exercise approach aimed at enhancing core muscle strength and endurance, postural control, and movement quality by targeting deep trunk muscle activation, lumbopelvic stability, and neuromuscular control. Although studies exist regarding Pilates interventions targeting the core region in individuals with PCOS, no study has been found that examines the effects of spinal stabilization exercises administered either in isolation or as an adjunct to aerobic exercise. Therefore, it is hypothesized that incorporating spinal stabilization exercises into an aerobic exercise regimen may provide additional benefits-particularly regarding metabolic, hormonal, and inflammatory outcomes, alongside physical fitness components.

The aim of this study is to comparatively examine the effects of spinal stabilization exercises added to aerobic exercise-versus aerobic exercise alone-on metabolic, hormonal, and inflammatory markers, anthropometric characteristics, cardiovascular fitness, core muscle strength and endurance, and quality of life in individuals with PCOS.

Panoramica dello studio

Descrizione dettagliata

Polycystic ovary syndrome (PCOS) is a common multisystem endocrine and metabolic disorder among women of reproductive age, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. In addition to reproductive disturbances, PCOS is associated with insulin resistance, chronic low-grade inflammation, hormonal imbalances, obesity, and an increased risk of long-term metabolic complications. These alterations may also negatively affect physical fitness, particularly cardiorespiratory fitness and muscular endurance. Furthermore, PCOS may be accompanied by psychosocial problems, including depression and anxiety, which may contribute to impaired quality of life.

Lifestyle interventions, particularly physical activity and exercise, are considered first-line strategies in the management of PCOS. Aerobic and resistance exercise have been shown to improve insulin resistance, cardiometabolic risk factors, hormonal profiles, inflammation, body composition, and reproductive outcomes. However, evidence regarding their effects on physical fitness components that may be impaired in PCOS, particularly cardiorespiratory fitness and muscular endurance, remains limited. Moreover, there is no clear consensus regarding the specific effectiveness of different exercise modalities, contents, and training volumes on physical fitness outcomes in women with PCOS.

Spinal stabilization exercises focus on activating the deep trunk muscles and improving lumbopelvic stability, neuromuscular control, core muscle strength and endurance, postural control, and movement quality. Considering the adverse effects of insulin resistance, chronic inflammation, and hormonal disturbances on muscle morphology and physical fitness in PCOS, spinal stabilization exercises may provide additional benefits in this population. Although Pilates-based interventions targeting the core region have demonstrated beneficial effects on quality of life, hormonal profiles, menstrual symptoms, and certain physical fitness parameters in women with PCOS, the effects of spinal stabilization exercises, either alone or in combination with aerobic exercise, have not yet been investigated in this population. Therefore, adding spinal stabilization exercises to aerobic exercise may provide additional benefits for metabolic and hormonal functions, body composition, cardiorespiratory fitness, and muscular endurance.

The aim of this study is to compare the effects of aerobic exercise combined with spinal stabilization exercises versus aerobic exercise alone on metabolic, hormonal, and inflammatory markers, anthropometric parameters, cardiorespiratory fitness, core muscle strength, core muscle endurance, and quality of life in individuals with PCOS.

Tipo di studio

Interventistico

Iscrizione (Stimato)

20

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Malatya
      • Malatya, Malatya, Turchia (Türkiye), 44280
        • Inönü University Department of Obstetrics and Gynecology

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 45 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Individuals aged 18-45 years (premenopausal) diagnosed with PCOS by an obstetrician-gynecologist, with a body mass index between 25 and 39.9 kg/m² and a physical activity level below 600 MET-min/week (inactive) according to the International Physical Activity Questionnaire-Short Form (IPAQ-SF) assessment.

Exclusion Criteria:

  • Pregnancy, diabetes, smoking, participation in a dietary intervention, congenital adrenal hyperplasia, thyroid diseases, hyperprolactinemia, Cushing's syndrome, or musculoskeletal disorders preventing exercise; use of antihypertensive medications, insulin-sensitizing drugs, nutritional supplements, or weight-loss medications

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: aerobic exercise group

The aerobic training group will undergo aerobic exercise on a treadmill three days a week for eight weeks under the supervision of a specialist physiotherapist. For patients with no prior treadmill experience, the first session will serve as a trial session to facilitate adaptation to the treadmill. In subsequent sessions, the aerobic training will be conducted in phases comprising warm-up, exertion, and cool-down periods.

Sperimentale: spinal stabilization exercise group combined with aerobic exercise

The aerobic training group will undergo aerobic exercise on a treadmill three days a week for eight weeks under the supervision of a specialist physiotherapist. For patients with no prior treadmill experience, the first session will serve as a trial session to facilitate adaptation to the treadmill. In subsequent sessions, the aerobic training will be conducted in phases comprising warm-up, exertion, and cool-down periods.

As a first step in spinal stabilization training, individuals will be instructed on proper postural alignment. To determine each individual's ideal posture, a neutral spine position-characterized by comfort and a lack of pain in the lumbopelvic region-will be identified in front of a mirror, and the contraction of deep muscles (abdominal bracing) will be taught. Individuals will be required to maintain proper posture and deep muscle group activation throughout the exercises. Stretching and mobility exercises targeting the lumbar region, trunk muscles, and lower extremities will be performed for approximately 5-10 minutes as part of the warm-up and cool-down periods surrounding the spinal stabilization exercises. The exercises will be conducted for approximately 30 minutes.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Fasting Blood Glucose Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Fasting blood glucose concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL.

At baseline and after 8 weeks of treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Fasting Serum Insulin Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Fasting serum insulin concentration will be measured from venous blood samples after an overnight fast and reported in µIU/mL.

At baseline and after 8 weeks of treatment
Fasting Serum Triglyceride Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Fasting serum triglyceride concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL.

At baseline and after 8 weeks of treatment
Serum High-Density Lipoprotein Cholesterol Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Serum high-density lipoprotein cholesterol (HDL-C) concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL.

At baseline and after 8 weeks of treatment
Serum Low-Density Lipoprotein Cholesterol Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Serum low-density lipoprotein cholesterol concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL.

At baseline and after 8 weeks of treatment
Serum Total Cholesterol Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Serum total cholesterol concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL.

At baseline and after 8 weeks of treatment
Serum Prolactin Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Serum prolactin concentration will be measured from venous blood samples after an overnight fast and reported in ng/mL.

At baseline and after 8 weeks of treatment
Serum Luteinizing Hormone Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Serum luteinizing hormone concentration will be measured from venous blood samples after an overnight fast and reported in mIU/mL.

At baseline and after 8 weeks of treatment
Serum Follicle-Stimulating Hormone Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Serum follicle-stimulating hormone concentration will be measured from venous blood samples after an overnight fast and reported in mIU/mL.

At baseline and after 8 weeks of treatment
Serum Thyroid-Stimulating Hormone Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Serum thyroid-stimulating hormone concentration will be measured from venous blood samples after an overnight fast and reported in µIU/mL.

At baseline and after 8 weeks of treatment
Serum High-Sensitivity C-Reactive Protein Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Serum high-sensitivity C-reactive protein concentration will be measured from venous blood samples after an overnight fast and reported in mg/L.

At baseline and after 8 weeks of treatment
Free Androgen Index
Lasso di tempo: At baseline and after 8 weeks of treatment

Free androgen index will be calculated using total testosterone and sex hormone-binding globulin concentrations and reported as a dimensionless value.

At baseline and after 8 weeks of treatment
Serum Estradiol Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Serum estradiol concentration will be measured from venous blood samples after an overnight fast and reported in pg/mL.

At baseline and after 8 weeks of treatment
Serum Sex Hormone-Binding Globulin Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Serum sex hormone-binding globulin concentration will be measured from venous blood samples after an overnight fast and reported in nmol/L.

At baseline and after 8 weeks of treatment
Serum Anti-Müllerian Hormone Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Serum anti-Müllerian hormone concentration will be measured from venous blood samples after an overnight fast and reported in ng/mL.

At baseline and after 8 weeks of treatment
Homeostatic Model Assessment of Insulin Resistance
Lasso di tempo: At baseline and after 8 weeks of treatment

Insulin resistance will be calculated using fasting glucose and fasting insulin concentrations according to the Homeostatic Model Assessment of Insulin Resistance formula and reported as an index value.

At baseline and after 8 weeks of treatment
Serum Interleukin-6 Concentration
Lasso di tempo: At baseline and after 8 weeks of treatment

Serum interleukin-6 concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in pg/mL.

At baseline and after 8 weeks of treatment
Serum Interleukin-10 Concentration
Lasso di tempo: At baseline and 8 weeks after treatment.

Serum interleukin-10 concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in pg/mL.

At baseline and 8 weeks after treatment.
Serum Tumor Necrosis Factor-Alpha Concentration
Lasso di tempo: At baseline and 8 weeks after treatment.

Serum tumor necrosis factor-alpha concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in pg/mL.

At baseline and 8 weeks after treatment.
Serum Adiponectin Concentration
Lasso di tempo: At baseline and 8 weeks after treatment.

Serum adiponectin concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in ng/mL.

At baseline and 8 weeks after treatment.
Serum Irisin Concentration.
Lasso di tempo: At baseline and 8 weeks after treatment.

Serum irisin concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in ng/mL.

At baseline and 8 weeks after treatment.
Waist-to-Hip Ratio
Lasso di tempo: At baseline and 8 weeks after treatment

Waist circumference and hip circumference will be measured in meters (m). The waist-to-hip ratio will be calculated by dividing waist circumference by hip circumference.

At baseline and 8 weeks after treatment
Waist-to-Height Ratio
Lasso di tempo: At baseline and 8 weeks after treatment

Waist circumference and height will be measured in meters (m). The waist-to-height ratio will be calculated by dividing waist circumference by height.

At baseline and 8 weeks after treatment
Anthropometric Measurement (Body Mass Index)
Lasso di tempo: At baseline and 8 weeks after treatment

Body mass index will be calculated as body weight in kilograms divided by height in meters squared and reported in kg/m².

At baseline and 8 weeks after treatment
Body Weight Assessed by Bioelectrical Impedance Analysis
Lasso di tempo: At baseline and 8 weeks after treatment

Body weight will be measured using a Tanita bioelectrical impedance analysis device and reported in kilograms (kg).

At baseline and 8 weeks after treatment
Body Fat Mass Assessed by Bioelectrical Impedance Analysis
Lasso di tempo: At baseline and 8 weeks after treatment

Body fat mass will be assessed using a Tanita bioelectrical impedance analysis device and reported in kilograms (kg).

At baseline and 8 weeks after treatment
Body Fat Percentage Assessed by Bioelectrical Impedance Analysis
Lasso di tempo: At baseline and 8 weeks after treatment

Body fat percentage will be assessed using a Tanita bioelectrical impedance analysis device and reported as a percentage (%).

At baseline and 8 weeks after treatment
Fat-Free Mass Assessed by Bioelectrical Impedance Analysis
Lasso di tempo: At baseline and 8 weeks after treatment

Fat-free mass will be assessed using a Tanita bioelectrical impedance analysis device and reported in kilograms (kg).

At baseline and 8 weeks after treatment
Body Muscle Percentage Assessed by Bioelectrical Impedance Analysis
Lasso di tempo: At baseline and 8 weeks after treatment

Body muscle percentage will be assessed using a Tanita bioelectrical impedance analysis device and reported as a percentage (%).

At baseline and 8 weeks after treatment
Total Body Water Assessed by Bioelectrical Impedance Analysis
Lasso di tempo: At baseline and 8 weeks after treatment

Total body water will be assessed using a Tanita bioelectrical impedance analysis device and reported in kilograms (kg).

At baseline and 8 weeks after treatment
Total Body Water Percentage Assessed by Bioelectrical Impedance Analysis
Lasso di tempo: At baseline and 8 weeks after treatment

Total body water percentage will be assessed using a Tanita bioelectrical impedance analysis device and reported as a percentage (%).

At baseline and 8 weeks after treatment
Visceral Fat Rating Assessed by Bioelectrical Impedance Analysis
Lasso di tempo: At baseline and 8 weeks after treatment

Visceral fat will be assessed using a Tanita bioelectrical impedance analysis device and reported as the visceral fat rating provided by the device.

At baseline and 8 weeks after treatment
Cardiovascular fitness (6-minute walk test)
Lasso di tempo: At baseline and 8 weeks after treatment

Cardiovascular fitness will be assessed using the 6-Minute Walk Test. Participants will be instructed to walk along a 30-meter corridor for 6 minutes at their usual walking pace. The total distance walked during 6 minutes will be recorded in meters (m).

At baseline and 8 weeks after treatment
Core muscle endurance (trunk flexor test)
Lasso di tempo: At baseline and 8 weeks after treatment

Trunk flexor endurance will be assessed using the McGill Trunk Flexor Test. Participants will maintain the standardized trunk flexion position for as long as possible. The duration for which the position is maintained will be recorded in seconds (s).

At baseline and 8 weeks after treatment
Core muscle endurance (trunk extensor test)
Lasso di tempo: At baseline and 8 weeks after treatment

Trunk extensor endurance will be assessed using the McGill Trunk Extensor Test. Participants will maintain the standardized horizontal trunk position for as long as possible. The duration for which the position is maintained will be recorded in seconds (s).

At baseline and 8 weeks after treatment
Core muscle endurance (side bridge test)
Lasso di tempo: At baseline and after 8 weeks of treatment

Lateral trunk muscle endurance will be assessed using the Side Bridge Test. Participants will maintain the standardized side bridge position for as long as possible. The duration for which the position is maintained will be recorded in seconds (s).

At baseline and after 8 weeks of treatment
Core muscle strength (sit-up test)
Lasso di tempo: At baseline and after 8 weeks of treatment

Core muscle strength will be assessed using the 30-second Sit-Up Test. Participants will perform as many sit-ups as possible within 30 seconds. The total number of correctly completed repetitions will be recorded.

At baseline and after 8 weeks of treatment
Core muscle strength (Modified Push-up test)
Lasso di tempo: At baseline and after 8 weeks of treatment

Core muscle strength will be assessed using the 30-second Modified Push-Up Test. Participants will perform as many modified push-ups as possible within 30 seconds. The total number of correctly completed repetitions will be recorded.

At baseline and after 8 weeks of treatment
Polycystic Ovary Syndrome Quality of Life-50 Scale
Lasso di tempo: At baseline and after 8 weeks of treatment

Quality of life will be assessed using the Polycystic Ovary Syndrome Quality of Life-50 Scale. The scale consists of 50 items across six domains: psychosocial and emotional status, fertility, sexual function, obesity and menstrual disorders, hirsutism, and coping with the disease. Each item is scored from 1 to 5, with a total score ranging from 50 to 250. Higher total scores indicate better quality of life.

At baseline and after 8 weeks of treatment
Patient's Perception of Global Change
Lasso di tempo: After 8 weeks of treatment

Participants' perceived change in polycystic ovary syndrome-related symptoms compared with baseline will be assessed using the Global Perceived Improvement Scale. The scale ranges from 1 to 7: 1 = very much better, 2 = much better, 3 = slightly better, 4 = no change, 5 = slightly worse, 6 = much worse, and 7 = very much worse. Lower scores indicate greater perceived improvement, whereas higher scores indicate greater perceived worsening.

After 8 weeks of treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 ottobre 2026

Completamento primario (Stimato)

20 gennaio 2027

Completamento dello studio (Stimato)

20 agosto 2027

Date di iscrizione allo studio

Primo inviato

30 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

6 ottobre 2026

Primo Inserito (Effettivo)

13 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi